Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:BXLT

(BXLT) (BXLT) Stock Price, News & Analysis

(BXLT) logo

About (BXLT) Stock (NYSE:BXLT)

Advanced Chart

Key Stats

Today's Range
$46.02
$46.02
50-Day Range
N/A
52-Week Range
$29.83
$46.52
Volume
N/A
Average Volume
12.66 million shs
Market Capitalization
N/A
P/E Ratio
15.49
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Receive BXLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (BXLT) and its competitors with MarketBeat's FREE daily newsletter.

BXLT Stock News Headlines

AnyMind Group Inc 5027
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
IDICO Corp JSC Ordinary Shares IDC
Hana Financial Group Inc 086790
See More Headlines

BXLT Stock Analysis - Frequently Asked Questions

(BXLT) (NYSE:BXLT) posted its quarterly earnings data on Thursday, April, 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.01. The company's quarterly revenue was up 10.3% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that (BXLT) investors own include Baxter International (BAX), Hawkins (HWKN), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Allergan (AGN), Bank of America (BAC) and Vertex Pharmaceuticals (VRTX).

Company Calendar

Last Earnings
4/28/2016
Today
5/21/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NYSE:BXLT
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
15.49
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:BXLT) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners